Pharmacy & Therapeutics - December 2008 - (Page 686)

MEDICATION ERRORS A Loud Wake-up Call Unlabeled Containers Can Lead to Fatalities Matthew Grissinger, RPh, FASCP Mr. Grissinger is Director of Error Reporting Programs at the Institute for Safe Medication Practices in Horsham, PA (www. ismp.org). PROBLEM: During a procedure for a coil placement in a female patient undergoing cerebral angiography to repair a brain aneurysm, clear chlorhexidine solution was placed in an unlabeled basin identical to a container used to hold contrast medium. Neither basin was labeled, so both solutions looked exactly the same. At the end of the procedure, contrast medium was to have been injected into the patient’s artery for radiographic visualization. Unfortunately, chlorhexidine was drawn into the syringe; the patient received the antiseptic, which is highly toxic when it is injected intravascularly. Within two hours, the patient suspected that something was very wrong. Acute, severe chemical injur y to the blood vessels of the leg restricted circulation to her muscles, causing profound injury and swelling of her leg. During the next two weeks, the patient’s condition deteriorated. She underwent a leg amputation and then suffered a stroke and multiple organ failure, which led to her death. The hospital’s recent decision to switch antiseptics from a brown povidone–iodine solution to a clear chlorhexidine solution resulted in an error that was not immediately apparent—two look-alike, clear solutions on the sterile field (the area immediately around a patient that has been prepared for a surgical procedure) that had previously been distinguished by color. This latent failure was revealed when the unlabeled solution basins were mixed up. Unlabeled medications and solutions on the sterile field have caused many other errors, some with tragic outcomes. One of our earliest reports at the Institute for Safe Medication Practices (ISMP) appeared in 1989 in the journal Hospital Pharmacy. A news reporter for the Miami Herald died during a surgical procedure to remove a cancerous eye. An unlabeled specimen cup filled with glutaraldehyde, which had been intended to preserve the patient’s enucleated eye, was misidentified as spinal fluid that had been removed to reduce cerebral pressure because the malignancy had spread to the brain. The spinal fluid was in an identical unlabeled cup. Near the end of the procedure, an anesthesiologist accidentally injected the glutaraldehyde intrathecally, believing it was the patient’s spinal fluid. The ISMP reported several errors in which unlabeled cups or basins on the sterile field led to errors. In one case, the patient received an injection of hydrogen peroxide instead of lidocaine for local anesthesia. Fortunately, the patient experienced no adverse drug reactions. Three other cases involved errors with unlabeled medication or solution containers in settings outside the operating room. One patient received lidocaine instead of contrast medium during angiography, leading to a grand mal seizure. In a similar setting, contrast medium instead of lidocaine was infiltrated around an injection site for local anesthesia just prior to angiography, and local tissue damage resulted. Another patient being treated in a hospital-based physician’s office sustained severe burns to his genitals when the physician mistakenly applied T.B.Q. Environmental Disinfectant Cleaner (Steris Corp.)—a cationic germicidal detergent with a pH of 13— from an unlabeled bottle. The physician thought that the bottle contained vinegar, which was needed to bleach the wart to make it more visible. These mishaps and the most recent tragic error should serve as a warning to minimize risks with unlabeled medications and solutions on the sterile field. Although many health care professionals might have not experienced a serious sentinel event despite poor labeling practices, no one should wait until a patient is harmed before taking action. SAFE PRACTICE RECOMMENDATION: Policies and procedures for safe labeling of medications and solutions used in perioperative settings must be developed and implemented in traditional operating rooms, ambulatory surgery units, labor and delivery rooms, physicians’ offices, cardiac catheterization and endoscopy suites, radiology departments, and other areas where invasive surgery may be performed. The Association of PeriOperative Registered Nurses (AORN) has issued some recommendations:1 1. Labels should be provided for all medication containers and solutions. a. Staff personnel can easily accomplish this step by buying sterile markers, blank labels, and preprinted labels. The labels can be prepared by the facility or can be purchased. They should be able to be opened onto the sterile field during all procedures. b. To minimize staff time, surgical packs can be prepared ahead of time with these markers and labels for all anticipated medications and solutions that will be needed for each case. 2. Labels should be required. a. All drugs, medication containers (such as syringes, medicine cups, and basins) and solutions should be labeled on and off the sterile field, even if only one product is involved. b. Labels should also be required on all solutions, chemicals, and reagents (e.g., formalin, saline, Lugol’s solution, and radiocontrast media) that are used in perioperative units. 3. Look-alike products must be differentiated from each other. a. If the names of a drug and another solution are similar, “tall man” lettering should be applied to these labels so that all staff members can easily distinguish one product from the other; alternatively, the distinguishing information on the label can be highlighted or circled. b. When possible, antiseptic products for the skin should be purchased in prepackaged swabs or sponges to clearly continued on page 732 686 P&T® • December 2008 • Vol. 33 No. 12 http://www.ismp.org http://www.ismp.org

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - December 2008

Pharmacy & Therapeutics - December 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/ New Medical Devices Drug Forecast Interpreting Estimates of Treatment Effects Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow Third Annual Onmark National Payor/Provider Forum Fourth Annual Ophthalmic Drug Development and Delivery Summit Classification and Pharmacological Management Of Obesity CE Test and Forms Season’s Greetings: Thanks to Our Readers and Reviewers

Pharmacy & Therapeutics - December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.